Skip to main content
Top
Published in: BMC Cancer 1/2004

Open Access 01-12-2004 | Research article

Characterization of a novel large deletion and single point mutations in the BRCA1gene in a Greek cohort of families with suspected hereditary breast cancer

Authors: Ioulia Belogianni, Angela Apessos, Markos Mihalatos, Evangelia Razi, Stefanos Labropoulos, Andreas Petounis, Vasiliki Gaki, Antonios Keramopoulos, Nikos Pandis, Kyriacos Kyriacou, Andreas Hadjisavvas, Paris Kosmidis, Drakoulis Yannoukakos, Georgios Nasioulas

Published in: BMC Cancer | Issue 1/2004

Login to get access

Abstract

Background

Germline mutations in BRCA1 and BRCA2 predispose to breast and ovarian cancer. A multitude of mutations have been described and are found to be scattered throughout these two large genes. We describe analysis of BRCA1 in 25 individuals from 18 families from a Greek cohort.

Methods

The approach used is based on dHPLC mutation screening of the BRCA1 gene, followed by sequencing of fragments suspected to carry a mutation including intron – exon boundaries. In patients with a strong family history but for whom no mutations were detected, analysis was extended to exons 10 and 11 of the BRCA2 gene, followed by MLPA analysis for screening for large genomic rearrangements.

Results

A pathogenic mutation in BRCA1 was identified in 5/18 (27.7 %) families, where four distinct mutations have been observed. Single base putative pathogenic mutations were identified by dHPLC and confirmed by sequence analysis in 4 families: 5382insC (in two families), G1738R, and 5586G > A (in one family each). In addition, 18 unclassified variants and silent polymorphisms were detected including a novel silent polymorphism in exon 11 of the BRCA1 gene. Finally, MLPA revealed deletion of exon 20 of the BRCA1 gene in one family, a deletion that encompasses 3.2 kb of the gene starting 21 bases into exon 20 and extending 3.2 kb into intron 20 and leads to skipping of the entire exon 20. The 3' breakpoint lies within an AluSp repeat but there are no recognizable repeat motifs at the 5' breakpoint implicating a mechanism different to Alu-mediated recombination, responsible for the majority of rearrangements in the BRCA1 gene.

Conclusions

We conclude that a combination of techniques capable of detecting both single base mutations and small insertions / deletions and large genomic rearrangements is necessary in order to accurately analyze the BRCA1 gene in patients at high risk of carrying a germline mutation as determined by their family history. Furthermore, our results suggest that in those families with strong evidence of linkage to the BRCA1 locus in whom no point mutation has been identified re-examination should be carried out searching specifically for genomic rearrangements.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nathanson KN, Wooster R, Webber BL: Breast cancer genetics: What we know and what we need. Nature Medicine. 2001, 7: 552-556. 10.1038/87876.CrossRefPubMed Nathanson KN, Wooster R, Webber BL: Breast cancer genetics: What we know and what we need. Nature Medicine. 2001, 7: 552-556. 10.1038/87876.CrossRefPubMed
2.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 . Science. 1994, 266: 66-71.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 . Science. 1994, 266: 66-71.CrossRefPubMed
3.
go back to reference Venkitaraman AR: Functions of BRCA1 and BRCA2 in the biological response to DNA damage. Journal of Cell Science. 2001, 114: 3591-3598.PubMed Venkitaraman AR: Functions of BRCA1 and BRCA2 in the biological response to DNA damage. Journal of Cell Science. 2001, 114: 3591-3598.PubMed
4.
go back to reference Deng C-X, Wang R-H: Roles of BRCA1 in DNA damage repair: a link between development and cancer. Human Molecular Genetics. 2003, 12: R113-R123. 10.1093/hmg/ddg082.CrossRefPubMed Deng C-X, Wang R-H: Roles of BRCA1 in DNA damage repair: a link between development and cancer. Human Molecular Genetics. 2003, 12: R113-R123. 10.1093/hmg/ddg082.CrossRefPubMed
5.
go back to reference Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BA, Barnes D, Eeles RA: The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res. 2000, 60: 4513-4518.PubMed Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BA, Barnes D, Eeles RA: The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res. 2000, 60: 4513-4518.PubMed
6.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, and the Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, and the Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral
8.
go back to reference Neuhausen SL: Ethnic differences in cancer risk resulting from genetic variation. Cancer. 1999, 86: 2575-2582. 10.1002/(SICI)1097-0142(19991201)86:11+<2575::AID-CNCR15>3.3.CO;2-6.CrossRefPubMed Neuhausen SL: Ethnic differences in cancer risk resulting from genetic variation. Cancer. 1999, 86: 2575-2582. 10.1002/(SICI)1097-0142(19991201)86:11+<2575::AID-CNCR15>3.3.CO;2-6.CrossRefPubMed
9.
go back to reference Steinberg KK, Pernarelli JM, Marcus M, Khoury MJ, Schildkraut JM, Marchbanks PA: Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study. Genet Epidemiol. 1998, 15: 51-59. 10.1002/(SICI)1098-2272(1998)15:1<51::AID-GEPI4>3.3.CO;2-T.CrossRefPubMed Steinberg KK, Pernarelli JM, Marcus M, Khoury MJ, Schildkraut JM, Marchbanks PA: Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study. Genet Epidemiol. 1998, 15: 51-59. 10.1002/(SICI)1098-2272(1998)15:1<51::AID-GEPI4>3.3.CO;2-T.CrossRefPubMed
10.
go back to reference Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS, Cooperative Family Registry for Breast Cancer studies: Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat. 2002, 20: 65-73. 10.1002/humu.10097.CrossRefPubMed Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS, Cooperative Family Registry for Breast Cancer studies: Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat. 2002, 20: 65-73. 10.1002/humu.10097.CrossRefPubMed
11.
go back to reference Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M: A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999, 105: 72-78. 10.1007/s004390051066.CrossRefPubMed Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M: A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999, 105: 72-78. 10.1007/s004390051066.CrossRefPubMed
12.
go back to reference Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D'Andrea E: Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet. 2003, 12: 1055-1061. 10.1093/hmg/ddg120.CrossRefPubMed Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D'Andrea E: Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet. 2003, 12: 1055-1061. 10.1093/hmg/ddg120.CrossRefPubMed
13.
go back to reference Barrois M, Bieche I, Mazoyer S, Champeme MH, Bressac-de Paillerets B, Lidereau R: Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. Clin Genet. 2004, 65: 131-136. 10.1111/j.0009-9163.2004.00200.x.CrossRefPubMed Barrois M, Bieche I, Mazoyer S, Champeme MH, Bressac-de Paillerets B, Lidereau R: Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. Clin Genet. 2004, 65: 131-136. 10.1111/j.0009-9163.2004.00200.x.CrossRefPubMed
14.
go back to reference Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M: Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat. 2002, 20: 218-226. 10.1002/humu.10108.CrossRefPubMed Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M: Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat. 2002, 20: 218-226. 10.1002/humu.10108.CrossRefPubMed
15.
go back to reference Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000, 67: 841-850. 10.1086/303076.CrossRefPubMedPubMedCentral Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000, 67: 841-850. 10.1086/303076.CrossRefPubMedPubMedCentral
16.
go back to reference Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S: Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 1999, 59: 455-461.PubMed Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S: Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 1999, 59: 455-461.PubMed
17.
go back to reference Ladopoulou A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schofield AC, Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Skarlos D, Haites NE, Fountzilas G, Pandis N, Yannoukakos D: Germ line BRCA1 and BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Letters. 2002, 185: 61-70. 10.1016/S0304-3835(01)00845-X.CrossRefPubMed Ladopoulou A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schofield AC, Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Skarlos D, Haites NE, Fountzilas G, Pandis N, Yannoukakos D: Germ line BRCA1 and BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Letters. 2002, 185: 61-70. 10.1016/S0304-3835(01)00845-X.CrossRefPubMed
18.
go back to reference Mihalatos M, Apessos A, Triantafillidis JK, Kosmidis PA, Fountzilas G, Agnantis NJ, Yannoukakos D, Nasioulas G: Evaluation of dHPLC in Mutation Screening of the APC Gene in a Greek FAP Cohort. Anticancer Res. 2003, 23: 2691-2696.PubMed Mihalatos M, Apessos A, Triantafillidis JK, Kosmidis PA, Fountzilas G, Agnantis NJ, Yannoukakos D, Nasioulas G: Evaluation of dHPLC in Mutation Screening of the APC Gene in a Greek FAP Cohort. Anticancer Res. 2003, 23: 2691-2696.PubMed
19.
go back to reference Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30: e57-10.1093/nar/gnf056.CrossRefPubMedPubMedCentral Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30: e57-10.1093/nar/gnf056.CrossRefPubMedPubMedCentral
20.
go back to reference Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS: The BRCA1 C-terminal domain: structure and function. Mutat Res. 2000, 460: 319-332. 10.1016/S0921-8777(00)00034-3.CrossRefPubMed Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS: The BRCA1 C-terminal domain: structure and function. Mutat Res. 2000, 460: 319-332. 10.1016/S0921-8777(00)00034-3.CrossRefPubMed
21.
go back to reference Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MB, Florentin L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, Yannoukakos D: BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Hum Mutat. 2000, 16: 272-273. 10.1002/1098-1004(200009)16:3<272::AID-HUMU17>3.0.CO;2-4.CrossRefPubMed Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MB, Florentin L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, Yannoukakos D: BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Hum Mutat. 2000, 16: 272-273. 10.1002/1098-1004(200009)16:3<272::AID-HUMU17>3.0.CO;2-4.CrossRefPubMed
22.
go back to reference Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, Gerdes AM, Moller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN: Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet. 2001, 10: 353-360. 10.1093/hmg/10.4.353.CrossRefPubMedPubMedCentral Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, Gerdes AM, Moller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN: Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet. 2001, 10: 353-360. 10.1093/hmg/10.4.353.CrossRefPubMedPubMedCentral
23.
go back to reference Hayes F, Cayanan C, Barilla D, Monteiro AN: Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res. 2000, 60: 2411-2418.PubMedPubMedCentral Hayes F, Cayanan C, Barilla D, Monteiro AN: Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res. 2000, 60: 2411-2418.PubMedPubMedCentral
24.
go back to reference Rohlfs EM, Puget N, Graham ML, Weber BL, Garber JE, Skrzynia C, Halperin JL, Lenoir GM, Silverman LM, Mazoyer S: An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer. 2000, 28: 300-307. 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1.CrossRefPubMed Rohlfs EM, Puget N, Graham ML, Weber BL, Garber JE, Skrzynia C, Halperin JL, Lenoir GM, Silverman LM, Mazoyer S: An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer. 2000, 28: 300-307. 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1.CrossRefPubMed
25.
go back to reference Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C, Pages S, Lynch HT, Goldgar D, Lenoir GM, Mazoyer S: An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?. Am J Hum Genet. 1999, 64: 300-302. 10.1086/302211.CrossRefPubMedPubMedCentral Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C, Pages S, Lynch HT, Goldgar D, Lenoir GM, Mazoyer S: An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?. Am J Hum Genet. 1999, 64: 300-302. 10.1086/302211.CrossRefPubMedPubMedCentral
26.
go back to reference Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K: Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst. 2004, 96: 68-70. 10.1093/jnci/djh006.CrossRefPubMed Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K: Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst. 2004, 96: 68-70. 10.1093/jnci/djh006.CrossRefPubMed
27.
go back to reference Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004, 96: 15-21. 10.1093/jnci/djh008.CrossRefPubMed Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004, 96: 15-21. 10.1093/jnci/djh008.CrossRefPubMed
28.
go back to reference Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002, 94: 1365-1372. 10.1093/jnci/94.18.1365.CrossRefPubMed Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002, 94: 1365-1372. 10.1093/jnci/94.18.1365.CrossRefPubMed
29.
go back to reference Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001, 68: 700-710. 10.1086/318787.CrossRefPubMedPubMedCentral Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001, 68: 700-710. 10.1086/318787.CrossRefPubMedPubMedCentral
30.
go back to reference Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M: Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999, 64: 1371-1377. 10.1086/302366.CrossRefPubMedPubMedCentral Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M: Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999, 64: 1371-1377. 10.1086/302366.CrossRefPubMedPubMedCentral
31.
go back to reference Ginolhac SM, Gad S, Corbex M, Bressac-De-Paillerets B, Chompret A, Bignon YJ, Peyrat JP, Fournier J, Lasset C, Giraud S, Muller D, Fricker JP, Hardouin A, Berthet P, Maugard C, Nogues C, Lidereau R, Longy M, Olschwang S, Toulas C, Guimbaud R, Yannoukakos D, Szabo C, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Goldgar D, Stoppa-Lyonnet D, Lenoir GM, Sinilnikova OM: BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. Cancer Epidemiol Biomarkers Prev. 2003, 12: 90-95.PubMed Ginolhac SM, Gad S, Corbex M, Bressac-De-Paillerets B, Chompret A, Bignon YJ, Peyrat JP, Fournier J, Lasset C, Giraud S, Muller D, Fricker JP, Hardouin A, Berthet P, Maugard C, Nogues C, Lidereau R, Longy M, Olschwang S, Toulas C, Guimbaud R, Yannoukakos D, Szabo C, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Goldgar D, Stoppa-Lyonnet D, Lenoir GM, Sinilnikova OM: BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. Cancer Epidemiol Biomarkers Prev. 2003, 12: 90-95.PubMed
Metadata
Title
Characterization of a novel large deletion and single point mutations in the BRCA1gene in a Greek cohort of families with suspected hereditary breast cancer
Authors
Ioulia Belogianni
Angela Apessos
Markos Mihalatos
Evangelia Razi
Stefanos Labropoulos
Andreas Petounis
Vasiliki Gaki
Antonios Keramopoulos
Nikos Pandis
Kyriacos Kyriacou
Andreas Hadjisavvas
Paris Kosmidis
Drakoulis Yannoukakos
Georgios Nasioulas
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2004
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-4-61

Other articles of this Issue 1/2004

BMC Cancer 1/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine